Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Wei Wang, Jorge E. Cortes, Pei Lin, Michael W. Beaty, Di Ai, Hesham M. Amin, Timothy J. McDonnell, Chi Young Ok, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu

Research output: Contribution to journalArticle

Abstract

Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26%; B, t(3;21)(q26.2;q22), 17%; C, other 3q26.2 rearrangements, 7%; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32%; and E, gain or loss of partial or whole chromosome3, 18%. In all, 3q26.2 rearrangements were the mostcommonchromosome3 abnormalities (50%, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. (Blood. 2015;126(14):1699-1706).

Original languageEnglish (US)
Pages (from-to)1699-1706
Number of pages8
JournalBlood
Volume126
Issue number14
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes
Chromosome Aberrations
Protein-Tyrosine Kinases
Blast Crisis
Survival
Acute Myeloid Leukemia
Cytogenetics
Blood
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. / Wang, Wei; Cortes, Jorge E.; Lin, Pei; Beaty, Michael W.; Ai, Di; Amin, Hesham M.; McDonnell, Timothy J.; Ok, Chi Young; Kantarjian, Hagop M.; Medeiros, L. Jeffrey; Hu, Shimin.

In: Blood, Vol. 126, No. 14, 01.10.2015, p. 1699-1706.

Research output: Contribution to journalArticle

Wang, W, Cortes, JE, Lin, P, Beaty, MW, Ai, D, Amin, HM, McDonnell, TJ, Ok, CY, Kantarjian, HM, Medeiros, LJ & Hu, S 2015, 'Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors', Blood, vol. 126, no. 14, pp. 1699-1706. https://doi.org/10.1182/blood-2015-05-646489
Wang, Wei ; Cortes, Jorge E. ; Lin, Pei ; Beaty, Michael W. ; Ai, Di ; Amin, Hesham M. ; McDonnell, Timothy J. ; Ok, Chi Young ; Kantarjian, Hagop M. ; Medeiros, L. Jeffrey ; Hu, Shimin. / Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. In: Blood. 2015 ; Vol. 126, No. 14. pp. 1699-1706.
@article{d15fc1b41fd2408ebf84f7b619157b38,
title = "Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors",
abstract = "Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8{\%}) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26{\%}; B, t(3;21)(q26.2;q22), 17{\%}; C, other 3q26.2 rearrangements, 7{\%}; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32{\%}; and E, gain or loss of partial or whole chromosome3, 18{\%}. In all, 3q26.2 rearrangements were the mostcommonchromosome3 abnormalities (50{\%}, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. (Blood. 2015;126(14):1699-1706).",
author = "Wei Wang and Cortes, {Jorge E.} and Pei Lin and Beaty, {Michael W.} and Di Ai and Amin, {Hesham M.} and McDonnell, {Timothy J.} and Ok, {Chi Young} and Kantarjian, {Hagop M.} and Medeiros, {L. Jeffrey} and Shimin Hu",
year = "2015",
month = "10",
day = "1",
doi = "10.1182/blood-2015-05-646489",
language = "English (US)",
volume = "126",
pages = "1699--1706",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

AU - Wang, Wei

AU - Cortes, Jorge E.

AU - Lin, Pei

AU - Beaty, Michael W.

AU - Ai, Di

AU - Amin, Hesham M.

AU - McDonnell, Timothy J.

AU - Ok, Chi Young

AU - Kantarjian, Hagop M.

AU - Medeiros, L. Jeffrey

AU - Hu, Shimin

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26%; B, t(3;21)(q26.2;q22), 17%; C, other 3q26.2 rearrangements, 7%; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32%; and E, gain or loss of partial or whole chromosome3, 18%. In all, 3q26.2 rearrangements were the mostcommonchromosome3 abnormalities (50%, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. (Blood. 2015;126(14):1699-1706).

AB - Chromosome 3q26.2 abnormalities in acute myeloid leukemia, including inv(3)/t(3;3) and t(3;21), have been studied and are associated with a poor prognosis. Their prevalence, response to tyrosine kinase inhibitor (TKI) treatment, and prognostic significance in chronic myelogenous leukemia (CML) are largely unknown. In this study, we explored these aspects using a cohort of 2013 patients with CML diagnosed in the era of TKI therapy. Chromosome 3 abnormalities were observed in 116 (5.8%) of 2013 cases. These cases were divided into 5 distinct groups: A, inv(3)(q21q26.2)/t(3;3)(q21;q26.2), 26%; B, t(3;21)(q26.2;q22), 17%; C, other 3q26.2 rearrangements, 7%; D, rearrangements involving chromosome 3 other than 3q26.2 locus, 32%; and E, gain or loss of partial or whole chromosome3, 18%. In all, 3q26.2 rearrangements were the mostcommonchromosome3 abnormalities (50%, groups A-C). 3q26.2 rearrangements emerged at different leukemic phases. For cases with 3q26.2 rearrangements that initially emerged in chronic or accelerated phase, they had a high rate of transformation to blast phase. Patients with 3q26.2 abnormalities showed a marginal response to TKI treatment, and no patients achieved a long-term sustainable response at a cytogenetic or molecular level. Compared with other chromosomal abnormalities in CML, patients with 3q26.2 rearrangements had poorer overall survival. The presence or absence of other concurrent chromosomal abnormalities did not affect survival in these patients, reflecting the predominant role of 3q26.2 rearrangements in determining prognosis. Interestingly, although heterogeneous, chromosome 3 abnormalities involving non-3q26.2 loci (groups D, E) also conferred a worse prognosis compared with changes involving other chromosomes in this cohort. (Blood. 2015;126(14):1699-1706).

UR - http://www.scopus.com/inward/record.url?scp=84947933015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947933015&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-05-646489

DO - 10.1182/blood-2015-05-646489

M3 - Article

C2 - 26243778

AN - SCOPUS:84947933015

VL - 126

SP - 1699

EP - 1706

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -